Koers ERYTECH Pharma LIQUIDNET SYSTEMS
Aandelen
FR0011471135
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 1,05 mln. 1,13 mln. | Omzet 2025 * | 1,6 mln. 1,72 mln. | Marktkapitalisatie | 12,15 mln. 13,05 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - 0 | Nettowinst (verlies) 2025 * | 1 mln. 1,07 mln. | EV/omzet 2024 * | 13,2 x |
Nettoschuld 2024 * | 1,7 mln. 1,83 mln. | Nettoschuld 2025 * | 15,25 mln. 16,38 mln. | EV/omzet 2025 * | 17,1 x |
K/w-verhouding 2024 * |
-1,1
x | K/w-verhouding 2025 * |
-2,2
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 95,71% |
Recentste transcriptie over ERYTECH Pharma
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 23-06-23 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 23-06-23 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 63 | 23-06-23 | |
Hilde Windels
BRD | Director/Board Member | 59 | 23-06-23 |
Gil Beyen
BRD | Director/Board Member | 62 | 23-06-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,82% | 121 mld. | |
+20,35% | 113 mld. | |
+17,47% | 26,02 mld. | |
-25,31% | 19,39 mld. | |
-19,51% | 15,91 mld. | |
-19,67% | 15,09 mld. | |
-46,87% | 15,06 mld. | |
+62,55% | 14,93 mld. | |
+6,34% | 13,85 mld. |